3rd Quarter - Report
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC for BOEHRINGER INGELHEIM USA CORPORATION
Firm
Income
—
Expenses
$530,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Patent Settlements; H.R. 1706 and S. 5369; Senate; Patent Bill (S. 23/H.R. 1249 -- America Invests Act)
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| PAUL ROMNESS | — |
Alcohol and Drug Abuse ALC
Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
Pharmacy PHA
Reauthorization of the Prescription Drug User Fee Act; Drug Safety
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| PAUL ROMNESS | — |
Budget/Appropriations BUD
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D/Debt Ceiling
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
Health Issues HCR
Health Care Reform; Patent and Affordable Care Act implementation - pricing/rebates; importation; coverage; Independent Patient Advisory Board
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| PAUL ROMNESS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.